首页> 外文OA文献 >Optimization of Imidazo4,5-bpyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia

【2h】

Optimization of Imidazo4,5-bpyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia

机译：咪唑基4,5-B吡啶基激酶抑制剂的优化：鉴定双重FLT3 / Aurora激酶抑制剂作为口服生物可利用的临床前培养基治疗急性髓性白血病

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Vassilios Bavetsias; Simon Crumpler; Chongbo Sun; Sian Avery; Butrus Atrash; Amir Faisal; Andrew S. Moore; Magda Kosmopoulou; Nathan Brown; Peter W. Sheldrake; Katherine Bush; Alan Henley; Gary Box; Melanie Valenti; Alexis de Haven Brandon; Florence I. Raynaud; Paul Workman; Suzanne A. Eccles; Richard Bayliss; Spiros Linardopoulos; Julian Blagg;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Optimization of imidazo[4,5- b]pyridine-based kinase inhibitors: Identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia [J] . Bavetsias V., Crumpler S., Sun C., Journal of Medicinal Chemistry . 2012,第20期

机译：基于咪唑并[4,5- b]吡啶的激酶抑制剂的优化：鉴定双重FLT3 /极光激酶抑制剂作为口服生物可利用的临床前发展候选药物，用于治疗急性髓细胞白血病
2. Imidazo[4,5-b]pyridine derivatives as inhibitors of aurora kinases: Lead optimization studies toward the identification of an orally bioavailable preclinical development candidate [J] . Bavetsias V., Large J.M., Sun C., Journal of Medicinal Chemistry . 2010,第14期

机译：咪唑并[4,5-b]吡啶衍生物作为极光激酶抑制剂：领先的优化研究，以鉴定口服生物利用度的临床前发展候选药物
3. Preclinical Evaluation of MAX-40279, a FLT3/FGFR Dual Kinase Inhibitor for Treatment of Acute Myeloid Leukemia [J] . Wang Yuguang, Bao Hanying, Zhang Nong, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：MAX-40279的临床前评价，一种用于治疗急性髓性白血病的FLT3 / FGFR双激酶抑制剂
4. Novel Inhibitors of T315I Mutant BCR-ABL1 Tyrosine Kinase for Chronic Myeloid Leukemia Disease Through Fragment-Based Drug Design [C] . Satya Anindita, Atika Marnolia, Hersal Hermana Putra, International symposium on bioinformatics research and applications . 2018

机译：T315I突变BCR-ABL1酪氨酸激酶的新型抑制剂通过基于片段的药物设计治疗慢性粒细胞白血病
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. Optimization of Imidazo45-bpyridine-Based Kinase Inhibitors: Identification of aDual FLT3/AuroraKinase Inhibitor as an Orally Bioavailable Preclinical DevelopmentCandidate for the Treatment of Acute Myeloid Leukemia [O] . Vassilios Bavetsias, *, Simon Crumpler, -1

机译：基于咪唑并45-b吡啶的激酶抑制剂的优化：双FLT3 / Aurora激酶抑制剂作为口服生物可用的临床前开发治疗急性髓性白血病的候选人
7. Correction to “Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms” [O] . Tao Yang, Mengshi Hu, Wenyan Qi, 2020

机译：“发现有效和口服有效的双janus激酶2 / flt3抑制剂治疗急性髓性白血病和myeloproiferative neoplasms的校正”

Optimization of Imidazo4,5-bpyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia

著录项

引文网络

相似文献

相关主题

期刊订阅